Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 231

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer

Open access
Stover, Daniel G., Parsons, Heather A., Ha, Gavin, Freeman, Samuel S., Barry, William T., Guo, Hao, Choudhury, Atish D., Gydush, Gregory, Reed, Sarah C., Rhoades, Justin, Rotem, Denisse, Hughes, Melissa E., Dillon, Deborah A., Partridge, Ann H., Wagle, Nikhil, Krop, Ian E., Getz, Gad, Golub, Todd R., Love, J. Christopher, Winer, Eric P., Tolaney, Sara M., Lin, Nancy U., Adalsteinsson, Viktor A. · 2018 · Journal of Clinical Oncology

Abstract

Purpose: Cell-free DNA (cfDNA) offers the potential for minimally invasive genome-wide profiling of tumor alterations without tumor biopsy and may be associated with patient prognosis. Triple-negative breast cancer (TNBC) is characterized by few mutations but extensive somatic copy number alterations (SCNAs), yet little is known regarding SCNAs in metastatic TNBC. We sought to evaluate SCNAs in metastatic TNBC exclusively via cfDNA and determine if cfDNA tumor fraction is associated with overall survival in metastatic TNBC. Patients and Methods: In this retrospective cohort study, we identified 164 patients with biopsy-proven metastatic TNBC at a single tertiary care institution who received prior chemotherapy in the (neo)adjuvant or metastatic setting. We performed low-coverage genome-wide sequencing of cfDNA from plasma. Results: Without prior knowledge of tumor mutations, we determined tumor fraction of cfDNA for 96.3% of patients and SCNAs for 63.9% of patients. Copy number profiles and percent genome altered were remarkably similar between metastatic and primary TNBCs. Certain SCNAs were more frequent in metastatic TNBCs relative to paired primary tumors and primary TNBCs in publicly available data sets The Cancer Genome Atlas and METABRIC, including chromosomal gains in drivers NOTCH2, AKT2, and AKT3. Prespecified cfDNA tumor fraction threshold of ≥ 10% was associated with significantly worse metastatic survival (median, 6.4 v 15.9 months) and remained significant independent of clinicopathologic factors (hazard ratio, 2.14; 95% CI, 1.4 to 3.8; P < .001). Conclusion: We present the largest genomic characterization of metastatic TNBC to our knowledge, exclusively from cfDNA. Evaluation of cfDNA tumor fraction was feasible for nearly all patients, and tumor fraction ≥ 10% is associated with significantly worse survival in this large metastatic TNBC cohort. Specific SCNAs are enriched and prognostic in metastatic TNBC, with implications for metastasis, resistance, and novel therapeutic approaches.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.76.0033

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 231

Metadata

Authors
Stover, D. G., Parsons, H. A., Ha, G., Freeman, S. S., Barry, W. T., Guo, H., Choudhury, A. D., Gydush, G., Reed, S. C., Rhoades, J., Rotem, D., Hughes, M. E., Dillon, D. A., Partridge, A. H., Wagle, N., Krop, I. E., Getz, G., Golub, T. R., Love, J. C., Winer, E. P., Tolaney, S. M., Lin, N. U., & Adalsteinsson, V. A.
Venue
Journal of Clinical Oncology
Published
2018-02-20
Volume
36
Issue
6
Pages
543-553
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2782274603
Cited by
231
References
11
FWCI
7.92
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. https://app.cochat.ai/papers/10.1200/jco.2017.76.0033
The paper
Stover, D. G., Parsons, H. A., Ha, G., Freeman, S. S., Barry, W. T., Guo, H., Choudhury, A. D., Gydush, G., Reed, S. C., Rhoades, J., Rotem, D., Hughes, M. E., Dillon, D. A., Partridge, A. H., Wagle, N., Krop, I. E., Getz, G., Golub, T. R., Love, J. C., . . . Adalsteinsson, V. A. (2018). Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.76.0033

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.